A phase III, open-label, extension, multi-center, safety and efficacy study of lisdexamfetamine dimesylate (LDX) in adolescents aged 13-17 with attention deficit/hyperactivity disorder (ADHD)

Trial Profile

A phase III, open-label, extension, multi-center, safety and efficacy study of lisdexamfetamine dimesylate (LDX) in adolescents aged 13-17 with attention deficit/hyperactivity disorder (ADHD)

Completed
Phase of Trial: Phase III

Latest Information Update: 04 Jun 2015

At a glance

  • Drugs Lisdexamfetamine (Primary)
  • Indications Attention-deficit hyperactivity disorder
  • Focus Therapeutic Use
  • Sponsors Shire
  • Most Recent Events

    • 07 Apr 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top